The impacts of maternal iron deficiency and being overweight during pregnancy on neurodevelopment of the offspring

Staffan K. Berglund1,2, Francisco J. Torres-Espínola1, Luz García-Valdés1, Mª Teresa Segura1, Cristina Martínez-Zaldívar1, Carmen Padilla3, Ricardo Rueda4, Miguel Pérez García5, Harry J. McArdle6 and Cristina Campoy1,7,8*

1EURISTIKOS Excellence Centre for Paediatric Research, University of Granada, 18016 Granada, Spain
2Department of Clinical Sciences, Pediatrics, Umeå University, 90185 Umeå, Sweden
3Clinical Service of Obstetrics and Gynaecology, Clinical University Hospital San Cecilio, 18012 Granada, Spain
4Abbott Laboratories, R&D Department, 18004 Granada, Spain
5Department of Clinical Neuropsychology, Mind, Brain and Behavior Research Centre, University of Granada, 18016 Granada, Spain
6The Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen AB21 9SB, UK
7Department of Paediatrics, University of Granada, 18004 Granada, Spain
8CIBER of Epidemiology and Public Health (CIBERESP), 18004 Granada, Spain

(Submitted 29 September 2016 – Final revision received 6 August 2017 – Accepted 15 August 2017)

Abstract
Both maternal Fe deficiency (ID) and being overweight or obese (Ow/Ob, BMI ≥25 kg/m²) may negatively affect offspring brain development. However, the two risk factors correlate and their independent effects on infant neurodevelopment are unclear. PREOBE is a prospective observational study that included 331 pregnant Spanish women, of whom 166 had pre-gestational Ow/Ob. Fe status was analysed at 34 weeks and at delivery, and babies were assessed using Bayley III scales of neurodevelopment at 18 months. In confounder-adjusted analyses, maternal ID at 34 weeks was associated with lower composite motor scores at 18 months (mean 113·3 (sd 9·9) v. 117·1 (sd 9·2), \( P=0.039 \)). Further, the offspring of mothers with ID at delivery had lower cognitive scores (114·0 (sd 9·7) v. 121·5 (sd 10·9), \( P=0.039 \) and lower receptive, expressive and composite (99·5 (sd 8·6) v. 107·6 (sd 8·3), \( P=0·004 \) language scores. The negative associations between maternal ID at delivery and Bayley scores remained even when adjusting for maternal Ow/Ob and gestational diabetes. Similarly, maternal Ow/Ob correlated with lower gross motor scores in the offspring (12·3 (sd 2·0) v. 13·0 (sd 2·1), \( P=0·037 \), a correlation that remained when adjusting for maternal ID. In conclusion, maternal ID and pre-gestational Ow/Ob are both negatively associated with Bayley scores at 18 months, independently and on different subscales. These results should be taken into account when considering Fe supplementation for pregnant women.

Key words: Iron: Overweight: Obesity: Infant neurodevelopment: Bayley test

The importance of the nutritional environment on brain development during fetal life and, particularly, during the third trimester has earned increasing interest\(^ {1–14} \). Several essential nutrients are now considered critical for both short- and long-term neurodevelopment of the unborn child. One such nutrient is Fe. Fe is essential for synaptogenesis, myelination and nerve-cell metabolism, and Fe deficiency (ID) during fetal or in early postnatal life is an established risk factor for poor neurodevelopment\(^ {1,5–7} \). Several groups that are at a risk for being Fe deficient, such as low-birth weight babies, babies born to diabetic mothers or children above 6 months of age with low Fe intake, have been studied in relation to their neurodevelopment, with negative associations found\(^ {8–11} \). Another possible risk group of prenatal or neonatal ID are the offspring of mothers with poor Fe status\(^ {12,13} \). Even though the placenta has an effective regulatory ability for Fe transfer, maternal ID has been associated with lower Fe stores in the fetus\(^ {12–17} \). However, few studies have explored the direct correlation between maternal ID and infant neurodevelopment, and the overall risk of adverse neurodevelopment following maternal ID has been considered low. Therefore, at least in developed countries, general Fe supplementation is currently not recommended\(^ {18,19} \).

Other fetal risk factors also associated with impaired neurodevelopment include maternal metabolic pathologies

Abbreviations: GD, gestational diabetes; ID, Fe deficiency; IDA, Fe deficiency anaemia; Ow/Ob, overweight or obese.

* Corresponding author: Professor C. Campoy, email ccampoy@ugr.es
such as being overweight (Ow), obesity (Ob) and gestational diabetes (GD). Offspring of mothers with these conditions show poorer long-term development of memory, motor development and overall cognition\(^\text{[20–23]}\). However, the mechanisms are unclear and causality is not yet determined; thus, confounding effects may possibly explain the associations. Interestingly, obesity is also known as a risk factor for ID, most likely caused by an increased inflammatory status and, consequently, by an up-regulation of the Fe-regulatory protein hepcidin\(^\text{[24–27]}\). This increased risk for ID in obese mothers may be a contributing confounder to the associations observed between maternal metabolic pathologies and neurodevelopment. It has recently been suggested that babies born to obese mothers may have reduced Fe stores, further supporting a link between the two conditions. Obesity is also known as a risk factor for ID, most likely caused by an increased inflammatory status and, consequently, by an up-regulation of the Fe-regulatory protein hepcidin\(^\text{[24–27]}\). This increased risk for ID in obese mothers may be a contributing confounder to the associations observed between maternal metabolic pathologies and neurodevelopment. It has recently been suggested that babies born to obese mothers may have reduced Fe stores, further supporting a link between the two conditions. Obesity is also known as a risk factor for ID, most likely caused by an increased inflammatory status and, consequently, by an up-regulation of the Fe-regulatory protein hepcidin\(^\text{[24–27]}\). This increased risk for ID in obese mothers may be a contributing confounder to the associations observed between maternal metabolic pathologies and neurodevelopment.

The PREOBE study is a prospective observational study with the general objective of studying the perinatal and postnatal influence of maternal Ow, Ob and GD on growth and neurodevelopment in the offspring, compared with healthy normal-weight controls\(^\text{[29]}\). The objectives of the current secondary analyses were to explore whether maternal ID and Ow/Ob are independently associated with neurodevelopment at 18 months of age in the offspring from the PREOBE cohort.

Methods

Study design and participants

The methodology of the present study has been published in detail elsewhere\(^\text{[29]}\). In brief, we included 331 women, pregnant between 2008 and 2012, through a collaboration with the tertiary ‘San Cecilio’ University Clinical Hospital and the Mother-Infant University Hospital in Granada (Spain). The inclusion criteria were singleton pregnancies, maternal age between 18 and 45 years, no simultaneous participation in any other research study, no kind of drug treatment, no diagnosed diseases other than obesity, Ow or GD (e.g. pre-GD or hypertension) and no unusual or vegan diets. Exclusion criteria used in the current analyses were preterm birth (<37 weeks of gestation) and congenital disorders in the offspring. As described elsewhere, we actively recruited women with different pre-gestational BMI including those of normal weight (18.5 kg/m\(^2\) ≤ BMI < 25 kg/m\(^2\)), those who were Ow (25 kg/m\(^2\) ≤ BMI < 30 kg/m\(^2\)) and those with obesity (BMI ≥ 30 kg/m\(^2\)). Further, we actively included mothers from all three BMI categories who were diagnosed with GD. The majority of mothers (n = 269) were approached and included at a gestational age of 12–20 weeks, during a screening visit at the obstetric clinic. However, to increase the number of included mothers diagnosed with GD, an additional recruitment of mothers (n = 62) was performed during a similar visit at a gestational age of 24–34 weeks\(^\text{[29]}\). The overall cohort included 166 women with pre-gestational Ow/Ob. A total of forty-six women had or were diagnosed with GD at 34 weeks of gestation. The remaining 165 cases had normal pre-gestational BMI. Of these, thirty-three had GD (Fig. 1).

The clinical practice for pregnant women in Spain follows recommendations from the Spanish society for gynaecology and obstetrics (www.sego.es). According to these recommendations, mothers diagnosed as being Ow/Ob are given weight-reducing nutritional advice. Further, mothers diagnosed with GD are routinely referred to an endocrinologist and a nutritionist, based on which they are given nutritional and lifestyle recommendations and, in some cases, insulin treatment to optimise glucose control\(^\text{[31]}\). Mothers included in the present study continued their ongoing regular check-ups and possible treatments at the obstetric and endocrinology clinic, in parallel with the data collection for the present study.

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures were approved by the Bioethical Committees for Clinical Research of the Clinical University Hospitals of Granada. Ethical approval was also obtained from the Research Bioethical Committee of the University of Granada. Written informed consent was obtained from all participants at study entry. The project was registered at www.ClinicalTrial.gov no.: NCT01634464.

Maternal and perinatal data collection

The details of the protocol were described previously\(^\text{[29]}\). During the screening visit at a gestational age of 12–20 weeks (or 24–34 weeks for the sixty-two mothers recruited in late pregnancy), and after signing the informed consent form, the mothers’ height and pre-gestational weight were measured. A questionnaire about the sociodemographic background (education, age, number of previous children, etc.) and ongoing Fe supplementation (present or not) was administered. The pre-gestational weight was self-reported, whereas the height was measured and the information was used to calculate the pre-gestational BMI. Thereafter, the mothers were invited for a visit at 24 and 34 weeks of gestation and were also assessed, whenever possible, at delivery. The data collection from the visit at 24 weeks is not included in the present analyses. The visit at 34 weeks of gestation and the assessment at delivery included anthropometric measurements and blood collection by venous puncture. Cord blood from the newborn infant was collected and analysed in all cases when it was available. Perinatal data were registered including mode of delivery, Apgar score, gestational age at birth, infant anthropometrics and any admission to the neonatal ward. Routine maternal check-ups in regular medical care – for example, Hb tests – were performed at the obstetric clinic in parallel with the present study and not monitored in detail.

At 3 months, the infant feeding mode was categorised by a paediatrician into exclusive breastfeeding, exclusive formula feeding or mixed feeding when breast milk and formula were combined.

Maternal and cord blood were analysed at the University Hospital laboratory for Hb and mean cell volume (MCV) using flow cytometry (ADVIA 2120; Siemens HealthCare); ferritin and transferrin were analysed using an automatic analyser (Elecsys 2010 with modular analytics E170; Roche); and Fe was analysed...
using enzyme-colorimetric automated methods for clinical chemistry (Modular Analytics EVO; Roche). Transferrin saturation (TS) was calculated using the formula: TS (%) = (ferritin (µg/ml) × 100)/transferrin (mg/dl) × 1.24. Maternal Fe-deficient erythropoiesis (ID) was defined when all three of the following variables were below the cut-off point according to Centers for Disease Control and Prevention: ferritin <15 µg/l; TS <16%; MCV <85 fl. Maternal Fe deficiency anaemia (IDA) was defined in those cases with ID and Hb below 110 g/l. Reduced Fe stores in cord blood were defined when ferritin in cord blood was below 35 µg/l. As presented previously, C-reactive protein (CRP) was only analysed in <50% of the cases and we chose not to adjust the Fe status measures for inflammation.

Neurodevelopmental assessment

Assessments of infant neurodevelopment at 18 months of age were conducted using the Bayley Scales of Infant Development, Third Edition (BSID-III). The BSID-III measures infant development across five domains: cognitive skills, receptive language, expressive language, fine motor development and gross motor development. The BSID-III was always performed in the research centre by the same trained psychologist (F. J. T.-E). Mothers also filled in the BSID-III questionnaire assessing the infants’ social–emotional behaviour.

Statistics

All statistical analyses were performed using the SPSS statistical software package for Windows (version 22.0; IBM SPSS Inc.). The subscales of Bayley scores were explored using a histogram and Q–Q plots and we assumed normal distribution as no significant skew was observed. Continuous variables were displayed as the mean values and standard deviations and explored using ANOVA, whereas categorical variables were compared using χ² or Fisher’s exact tests.

In the present analyses, we explored the association of Bayley scores at 18 months with the following risk factors: maternal Ow/Ob, maternal ID at 34 weeks and maternal ID at delivery. Maternal IDA at 34 weeks and at delivery as well as maternal Ow/Ob, maternal ID at 34 weeks and maternal ID at delivery. Maternal Fe-defi ciency anaemia (IDA) was deﬁned in those cases with ID and Hb below 110 g/l. Reduced Fe stores in cord blood were deﬁned when ferritin in cord blood was below 35 µg/l. As presented previously, C-reactive protein (CRP) was only analysed in <50% of the cases and we chose not to adjust the Fe status measures for inﬂammation.

The PREOBE project originally included four different groups, depending on maternal BMI and diabetic status (normal weight, Ow, Ob or GD). The pre-study power calculation aimed to detect differences in birth weight of 0.8% (assumed standard deviation = 1.5%) between the different groups and the minimum group size for each group was set to thirty-seven mother–child pairs, assuming a drop-out rate of 25% until delivery.

For the present secondary analyses, no pre-study power calculation was performed.

Results

Analysed subjects and their characteristics

The study profile for the current study is presented in Fig. 1. We excluded seven cases from all analyses because of preterm birth (n 5) or congenital disorders diagnosed after birth (n 2). The drop-out rate was low before delivery (n 21 (6%)) but following a large dropping out between birth and 18 months (n 109 (35%)), a sample of 194 children were assessed using the Bayley test at 18 months. The reasons for dropping out were mostly not reported by the mothers. Unfortunately, information about maternal Fe status at 34 weeks and at delivery were not available in all cases analysed for Bayley scores. The background and baseline characteristics and the prevalence of maternal ID and IDA of the analysed cases are presented in Table 1.

Effects of iron status on neurodevelopment

The results of the analyses of Bayley scores compared between ID and non-ID cases are presented in Tables 2 and 3. The offspring from mothers with ID at 34 weeks had significantly lower composite motor scores at 18 months of age. Maternal ID at delivery was negatively associated with lower receptive, expressive and composite language scores as well as with lower cognitive scores at 18 months. All associations remained significant after adjustment for background confounders and for GD. The correlation between maternal ID at delivery and the cognitive and language scores at 18 months all remained significant even when adjusting for maternal Ow/Ob.

Effects of overweight/obesity

We have previously presented data of Bayley scores using an alternative stratification and sample. In that study, we found that offspring of obese, non-diabetic mothers showed a trend of lower scores in motor development and no differences in language and cognitive scores at 18 months. In the present analyses, we compared the offspring of mothers who were Ow/Ob with those of normal-weight mothers and explored the effect, adjusted for maternal ID (Table 4). The results showed significantly lower gross motor scores in this group. The differences remained significant after adjusting for sex, gestational age at birth, for maternal education level and also in statistical models adjusting for ID at 34 weeks and ID at delivery, respectively.
In the present study, we explored how maternal ID and maternal Ow/Ob associated with Bayley scores of the offspring at 18 months of age. We found that composite motor scores were negatively associated with maternal ID at 34 weeks of gestation, and cognitive and language scores were negatively associated with maternal ID at delivery. The associations with ID at delivery remained both after adjusting for confounders and when adjusting for maternal Ow/Ob and GD. Presence of maternal Ow/Ob correlated negatively to another subscale at 18 months, the gross motor scores. The fact that the associations between maternal characteristics and Bayley scores at 18 months, in most cases, remained significant after adjusting for each other suggests that both maternal ID and maternal Ow/Ob contribute to a risk for impaired neurodevelopment.

Fe is essential for optimal brain function, being involved in neurotransmitter synthesis, cellular metabolism and myelination of neurons\(^1,10\). There is convincing evidence from previous trials that ID in fetal life and early infancy are associated with poor neurodevelopment\(^5-7,35\). Nevertheless, the exact risk contribution of ID at different severity and doses to different stages of brain development is still unclear, particularly, in human research\(^11,6,24\).

Because of high Fe requirements in both the fetus and the mother, maternal ID is a common condition in pregnancy\(^36,37\). The rationale for identifying it as a risk factor in infant neurodevelopment is that the fetus receives reduced placental transfer of Fe, causing either reduced Fe stores for the important 1st month of postnatal brain development, when Fe requirements in the infant are largely met by the inborn stores\(^24,38\), or direct prenatal compromise during fetal brain development\(^16,9,39\). The magnitude of this risk has previously been considered low, because of the efficient Fe uptake mechanism in the placenta. However, this has been questioned over the last few years, as several studies have shown that fetal Fe stores can still be compromised when the mother is Fe deficient\(^12-16\). Further, Lozoff \textit{et al.}\(^17\) recently showed in a randomised controlled trial that Fe supplementation to a pregnant woman at risk for ID, improved the Fe stores in the offspring until 9 months of age.

Although limited by its observational design, our results support the hypothesis that maternal ID during the third trimester constitutes a possible risk for sub-optimal brain development in the offspring. Few studies explored the association between maternal ID and offspring neurodevelopment. A recent micronutrient supplementation trial in pregnant women in rural China found that infants born to mothers with prenatal IDA had a lower mental development index until...
Table 1. Background and baseline characteristics in 183 mother–child pairs analyzed in the present study (Mean values and standard deviations; numbers and percentages)

<table>
<thead>
<tr>
<th>Maternal characteristics</th>
<th>n</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age at study entry (years)</td>
<td>183</td>
<td>31.9</td>
<td>4.3</td>
</tr>
<tr>
<td>Education at university level</td>
<td>183</td>
<td>85</td>
<td>46.4</td>
</tr>
<tr>
<td>Previous siblings</td>
<td>182</td>
<td>83</td>
<td>45.6</td>
</tr>
<tr>
<td>Maternal pre-gestational BMI (kg/m²)</td>
<td>183</td>
<td>26.0</td>
<td>5.1</td>
</tr>
<tr>
<td>Maternal Ow/Ob</td>
<td>183</td>
<td>90</td>
<td>49.2</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>183</td>
<td>44</td>
<td>24.0</td>
</tr>
<tr>
<td>Fe supplementation at entry</td>
<td>163</td>
<td>56</td>
<td>34.4</td>
</tr>
<tr>
<td>Maternal Fe status</td>
<td>175</td>
<td>82</td>
<td>46.3</td>
</tr>
<tr>
<td>Ferritin at 34 weeks (µg/l)</td>
<td>177</td>
<td>16.7</td>
<td>8.9</td>
</tr>
<tr>
<td>Hb at 34 weeks (g/l)</td>
<td>179</td>
<td>116.7</td>
<td>12.4</td>
</tr>
<tr>
<td>MCV at 34 weeks (fl)</td>
<td>179</td>
<td>86.7</td>
<td>4.9</td>
</tr>
<tr>
<td>Transferin saturation at 34 weeks (%)</td>
<td>178</td>
<td>16.8</td>
<td>10.8</td>
</tr>
<tr>
<td>Ferritin below 15µg/l at 34 weeks</td>
<td>177</td>
<td>82</td>
<td>46.3</td>
</tr>
<tr>
<td>ID at 34 weeks</td>
<td>175</td>
<td>34</td>
<td>19.4</td>
</tr>
<tr>
<td>IDA at 34 weeks</td>
<td>175</td>
<td>18</td>
<td>10.3</td>
</tr>
<tr>
<td>Ferritin at delivery (µg/l)</td>
<td>140</td>
<td>24.4</td>
<td>12.2</td>
</tr>
<tr>
<td>Hb at delivery (g/l)</td>
<td>137</td>
<td>120.3</td>
<td>18.5</td>
</tr>
<tr>
<td>MCV at delivery (fl)</td>
<td>137</td>
<td>86.9</td>
<td>5.4</td>
</tr>
<tr>
<td>Transferin saturation at delivery (%)</td>
<td>140</td>
<td>17.4</td>
<td>11.9</td>
</tr>
<tr>
<td>Ferritin below 15µg/l at delivery</td>
<td>140</td>
<td>23</td>
<td>16.4</td>
</tr>
<tr>
<td>ID at delivery</td>
<td>130</td>
<td>10</td>
<td>7.7</td>
</tr>
<tr>
<td>IDA at delivery</td>
<td>130</td>
<td>4</td>
<td>3.1</td>
</tr>
<tr>
<td>Infant characteristics</td>
<td>183</td>
<td>94</td>
<td>51.4</td>
</tr>
<tr>
<td>Boys</td>
<td>183</td>
<td>39.6</td>
<td>1.1</td>
</tr>
<tr>
<td>Birth length (cm)</td>
<td>169</td>
<td>50.5</td>
<td>2.0</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>183</td>
<td>3.33</td>
<td>0.43</td>
</tr>
<tr>
<td>Head circumference at birth (cm)</td>
<td>147</td>
<td>34.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Apgar score at 5 min</td>
<td>145</td>
<td>9.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Exclusive breast-feeding at 3 months</td>
<td>179</td>
<td>89</td>
<td>49.7</td>
</tr>
<tr>
<td>Ferritin below 35µg/l in cord blood</td>
<td>79</td>
<td>2</td>
<td>2.5</td>
</tr>
</tbody>
</table>

Maternal characteristics: Ow/Ob: overweight or obese (BMI ≥25 kg/m²); MCV, mean cell volume; ID, Fe deficiency; IDA, Fe deficiency anaemia.

24 months of age, whereas there was no association with ID without anaemia⁴⁰. In contrast to these results, we found a negative association between ID and neurodevelopment, even though the prevalence of IDA was relatively low among pregnant mothers. In fact, the prevalence of IDA even decreased between 34 weeks of gestation and delivery, most likely due to Fe supplementation, confirming that the explored cohort was at low risk for IDA.

A negative association between neurodevelopment and early stages of maternal ID is further supported by two recent animal models⁴¹,⁴² and from an observational study where the authors observed a significant association between maternal Fe intake and directional diffusion of water in the infant brain, measured using magnetic resonance⁴³.

From a clinical perspective, the present study gives further support to the policy of general Fe supplementation programmes in pregnant women. Few randomised studies have assessed the effect of maternal Fe supplementation on long-term offspring neurodevelopment. One study, following the offspring of Australian mothers who were randomly assigned to Fe supplements or placebo during pregnancy, failed to show any positive effect on cognition at 4 years of age, or behaviour at 6–8 years of age⁴⁴,⁴⁵. The mothers in the Australian trial were given general supplementation and the effects on neurodevelopment were not separately analysed for mothers with ID or IDA at baseline. Mainly on the basis of these Australian results, Cochrane, a consensus paper from the Committee on Nutrition of the European Society for Gastroenterology, Hepatology, and Nutrition (ESPGHAN) and a recent meta-analysis all concluded that there is no convincing evidence that Fe supplementation to a non-anaemic woman would improve neurodevelopment in the infant⁴⁶,⁴⁷. With regard to populations with a higher prevalence of ID and IDA, there are also few long-term follow-up studies available. The Chinese study above found no overall effect on Bayley scores following maternal supplementation⁴⁰. We conclude, supported by our observation and the lack of previous data, that further long-term studies exploring the effect of Fe supplementation in different populations are warranted. In such studies, the possible adverse effects of Fe supplementation should be evaluated as well.

Our results with regard to the association between neurodevelopment and maternal Ow and Ob have been discussed in detail elsewhere⁴⁸. In the present analyses we used an alternative approach of analysing the risk by adding all Ow and Ob mothers together, regardless of GD, and showed that this risk factor associated negatively with the gross motor score even after adjusting for gestational age, sex, maternal educational level and maternal ID.

This study was limited by its observational design, making possible causality difficult to explore. Confounding effects from non-monitored dietary, sociodemographic and genetic factors may be present. Further limitations were the lack of details regarding type, duration and dose of maternal Fe supplementations as well as a lack of inflammatory markers. There is a potential risk that a few cases of ID are incorrectly considered as non-ID because of concurrent inflammation. However, out of ninety-four CRP measures at 34 weeks of gestation, only one case had a CRP value above 5, suggesting a low risk for such a biased effect. Moreover, we did not adjust for the multiple testing, causing a possible risk for false positive findings, and there were a limited number of mothers participating in the
Table 2. Bayley scores at 18 months of age compared between children born to mothers with and those without Fe deficiency (ID) at 34 weeks of gestation (Mean values and standard deviations)

<table>
<thead>
<tr>
<th>Bayley scores at 18 months</th>
<th>ID (34 weeks, n 34)</th>
<th>Non-ID (34 weeks, n 141)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Composite language</td>
<td>106.7</td>
<td>8.1</td>
</tr>
<tr>
<td>Expressive language</td>
<td>10.6</td>
<td>1.8</td>
</tr>
<tr>
<td>Receptive language</td>
<td>11.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Composite motor</td>
<td>117.1</td>
<td>9.2</td>
</tr>
<tr>
<td>Fine motor</td>
<td>12.3</td>
<td>1.8</td>
</tr>
<tr>
<td>Gross motor</td>
<td>12.6</td>
<td>2.4</td>
</tr>
<tr>
<td>Composite cognitive</td>
<td>118.7</td>
<td>10.9</td>
</tr>
<tr>
<td>Composite socio-emotional</td>
<td>99.6</td>
<td>18.1</td>
</tr>
</tbody>
</table>

*P₁: value for unadjusted difference (t test).
† P₂: value for differences adjusted for sex, maternal education and gestational age at birth (ANCOVA).
‡ P₃: value for differences adjusted for sex, maternal education, gestational age at birth and maternal obesity/overweight (ANCOVA).
§ P₄: value for differences adjusted for sex, maternal education, gestational age at birth and gestational diabetes (ANCOVA).

Table 3. Bayley scores at 18 months of age compared between children born to mothers with and those without Fe deficiency (ID) at delivery (Mean values and standard deviations)

<table>
<thead>
<tr>
<th>Bayley scores at 18 months</th>
<th>ID delivery (n 10)</th>
<th>Non-ID delivery (n 120)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Composite language</td>
<td>99.5</td>
<td>8.6</td>
</tr>
<tr>
<td>Expressive language</td>
<td>9.0</td>
<td>1.8</td>
</tr>
<tr>
<td>Receptive language</td>
<td>10.8</td>
<td>1.4</td>
</tr>
<tr>
<td>Composite motor</td>
<td>115.8</td>
<td>12.8</td>
</tr>
<tr>
<td>Fine motor</td>
<td>12.2</td>
<td>2.0</td>
</tr>
<tr>
<td>Gross motor</td>
<td>13.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Composite cognitive</td>
<td>114.0</td>
<td>9.7</td>
</tr>
<tr>
<td>Composite socio-emotional</td>
<td>96.0</td>
<td>12.2</td>
</tr>
</tbody>
</table>

* P₁: value for unadjusted difference (t test).
† P₂: value for differences adjusted for sex, maternal education and gestational age at birth (ANCOVA).
‡ P₃: value for differences adjusted for sex, maternal education, gestational age at birth and maternal obesity/overweight (ANCOVA).
§ P₄: value for differences adjusted for sex, maternal education, gestational age at birth and gestational diabetes (ANCOVA).

Table 4. Bayley scores at 18 months of age compared between children born to mothers with and those without overweight or obesity (Ow/Ob) (BMI > 25 kg/m²) (Mean values and standard deviations)

<table>
<thead>
<tr>
<th>Bayley scores at 18 months</th>
<th>Ow/Ob (n 58)</th>
<th>Non-Ow/Ob (n 67)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Composite language</td>
<td>106.2</td>
<td>7.6</td>
</tr>
<tr>
<td>Expressive language</td>
<td>10.5</td>
<td>1.9</td>
</tr>
<tr>
<td>Receptive language</td>
<td>11.7</td>
<td>1.2</td>
</tr>
<tr>
<td>Composite motor</td>
<td>115.3</td>
<td>9.3</td>
</tr>
<tr>
<td>Fine motor</td>
<td>12.7</td>
<td>2.1</td>
</tr>
<tr>
<td>Gross motor</td>
<td>12.3</td>
<td>2.0</td>
</tr>
<tr>
<td>Composite cognitive</td>
<td>120.7</td>
<td>11.9</td>
</tr>
<tr>
<td>Composite socio-emotional</td>
<td>99.4</td>
<td>17.4</td>
</tr>
</tbody>
</table>

ID, Fe deficiency.
* P₁: value for unadjusted difference (t test).
† P₂: value for differences adjusted for sex, maternal education and gestational age at birth (ANCOVA).
‡ P₃: value for differences adjusted for sex, maternal education, gestational age at birth and BMI at 34 weeks of gestation (ANCOVA).
§ P₄: value for differences adjusted for sex, maternal education, gestational age at birth and maternal ID at delivery (ANCOVA).
† Significant P < 0.05.

Follow-up investigation at delivery, making the study population different when comparing the risk contribution at different stages of gestation. Finally, cord blood ferritin was only available in less than half of the cases of maternal ID and we could not statistically evaluate if the negative associations between Bayley scores and maternal ID was linked to infant ferritin levels. Nevertheless, the sample size in this prospective study was relatively high, there are good data from animal models for mechanistic explanations and the present analyses were adjusted for the most relevant confounders. Further, we have
performed novel analyses including both maternal Fe status and metabolic risk factors. To our knowledge, this mother–child cohort is one of the largest to include both maternal and infant data collection. As discussed, our observations are in line with previously discussed hypotheses and contribute with important data for further large-scale intervention studies.

Conclusions

In this study, we found that ID in late pregnancy is associated with impaired motor, cognitive and language development in the offspring at 18 months of life. The associations with regard to language and cognitive scores were independent of background factors, maternal Ow/Ob and GD, and possibly represented a causal correlation. Further, we found that maternal ID in late pregnancy did not explain the negative effect of Ow/Ob observed on gross motor development. The results suggest that both maternal Ow/Ob and maternal ID are negatively associated with child neurodevelopment but at different subscales and that they should be considered independently of each other. Consequently, the children of pregnant women with simultaneous Ow/Ob and ID are particularly at a risk for slower neurodevelopment because of a double burden of risk. Future research to verify and clarify the mechanisms underlying the observed associations are required, preferably including long-term neurodevelopmental follow-up studies. We believe that these results should be taken into account when considering whether to provide Fe supplementation for pregnant women in general and obese pregnant women in particular.

Acknowledgements

The authors thank the women and children who participated in the study and also the obstetricians, paediatricians and technicians of the EURISTIKOS team at the Department of Pediatrics at the University of Granada, Spain.

This study received grants from Spanish Ministry of Innovation and Science, Junta de Andalucia: Excellence Projects, ref: P06-CTS-02341; Spanish Ministry of Economy and Competitiveness, ref: BFU2012-40254-C03-01; and MyNewGut FP7 EU Project (grant agreement no. 613979). Further support was received from Abbott Nutrition, Granada, Spain. The authors declare that there are no conflicts of interest.

References